

Christine Lebrun-frenay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4173563/publications.pdf>

Version: 2024-02-01

170
papers

9,174
citations

44069

48
h-index

46799

89
g-index

231
all docs

231
docs citations

231
times ranked

9731
citing authors

#	ARTICLE	IF	CITATIONS
1	CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	10
2	Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study. <i>Neurology and Therapy</i> , 2022, 11, 633-658.	3.2	3
3	Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsingâ€œRemitting Multiple Sclerosis After Fingolimod Withdrawal. <i>Neurotherapeutics</i> , 2022, 19, 476-490.	4.4	5
4	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1424-1456.	3.0	16
5	Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. <i>Journal of Neuroinflammation</i> , 2022, 19, 62.	7.2	30
6	Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities. <i>Frontiers in Immunology</i> , 2022, 13, 864133.	4.8	5
7	From the prodromal stage of multiple sclerosis to disease prevention. <i>Nature Reviews Neurology</i> , 2022, 18, 559-572.	10.1	23
8	BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1556-1563.	3.0	9
9	Oral norgestrel acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1458-1463.	3.0	8
10	Atypical myelitis in patients with multiple sclerosis: Characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Multiple Sclerosis Journal</i> , 2021, 27, 232-238.	3.0	5
11	Pregnancy with multiple sclerosis. <i>Revue Neurologique</i> , 2021, 177, 180-194.	1.5	23
12	Digital biomarkers can highlight subtle clinical differences in radiologically isolated syndrome compared to healthy controls. <i>Journal of Neurology</i> , 2021, 268, 1316-1322.	3.6	5
13	Alexithymia in multiple sclerosis: Clinical and radiological correlations. <i>Revue Neurologique</i> , 2021, 177, 302-311.	1.5	7
14	Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis. <i>Neurotherapeutics</i> , 2021, 18, 378-386.	4.4	5
15	Cerebellar volume loss in radiologically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2021, 27, 130-133.	3.0	18
16	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	3.0	3
17	Untreated patients with multiple sclerosis: A study of French expert centers. <i>European Journal of Neurology</i> , 2021, 28, 2026-2036.	3.3	8
18	Hemophagocytic Lymphohistiocytosis Gene Mutations in Adult Patients Presenting With CLIPPERS-Like Syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	13

#	ARTICLE	IF	CITATIONS
19	Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. <i>Current Opinion in Neurology</i> , 2021, 34, 322-328.	3.6	23
20	Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis. <i>Neurotherapeutics</i> , 2021, 18, 938-948.	4.4	9
21	MRI findings in blinded trials should be available to treating physicians – Yes. <i>Multiple Sclerosis Journal</i> , 2021, 27, 812-813.	3.0	1
22	Comparison of Simoa TM and Ella TM to assess serum neurofilament ^{light} chain in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1141-1150.	3.7	45
23	Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	12
24	Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2280-2283.	3.0	9
25	Cerebrospinal Fluid IL-17A Could Predict Acute Disease Severity in Non-NMDA-Receptor Autoimmune Encephalitis. <i>Frontiers in Immunology</i> , 2021, 12, 673021.	4.8	14
26	The effectiveness of natalizumab vs fingolimod – A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012.	2.0	8
27	How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP). <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103076.	2.0	13
28	The multiple sclerosis prodrome is just unspecific symptoms in radiologically isolated syndrome patients – No. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1824-1826.	3.0	5
29	Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial. <i>Revue Neurologique</i> , 2021, , .	1.5	0
30	Association of Immunosuppression and Viral Load With Subcortical Brain Volume in an International Sample of People Living With HIV. <i>JAMA Network Open</i> , 2021, 4, e2031190.	5.9	16
31	Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. <i>JAMA Network Open</i> , 2021, 4, e2128271.	5.9	32
32	Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. <i>JAMA Neurology</i> , 2020, 77, 94.	9.0	36
33	Validation of a rapid and easy-to-perform screening test for neurocognitive impairment in HIV+ patients. <i>Journal of the Neurological Sciences</i> , 2020, 410, 116664.	0.6	3
34	Effects on Melanoma Cell Lines Suggest No Significant Risk of Melanoma Under Cladribine Treatment. <i>Neurology and Therapy</i> , 2020, 9, 599-604.	3.2	7
35	Radiologically Isolated Syndrome: $<sc>10\text{€}year</sc>$ Risk Estimate of a Clinical Event. <i>Annals of Neurology</i> , 2020, 88, 407-417.	5.3	95
36	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1079.	9.0	357

#	ARTICLE	IF	CITATIONS
37	Video-oculography in multiple sclerosis: Links between oculomotor disorders and brain magnetic resonance imaging (MRI). <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101969.	2.0	8
38	Outcome and risk of recurrence in a large cohort of idiopathic longitudinally extensive transverse myelitis without AQP4/MOG antibodies. <i>Journal of Neuroinflammation</i> , 2020, 17, 128.	7.2	13
39	Covid-19, the pandemic war: Implication for neurologists. <i>Revue Neurologique</i> , 2020, 176, 223-224.	1.5	9
40	Imaging spectrum of Bing-Neel syndrome: how can a radiologist recognise this rare neurological complication of Waldenström's macroglobulinemia?. <i>European Radiology</i> , 2019, 29, 102-114.	4.5	26
41	Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. <i>Neurology</i> , 2019, 93, e635-e646.	1.1	36
42	Prospective validation of the PML risk biomarker I-selectin and influence of natalizumab extended intervals. <i>Neurology</i> , 2019, 93, 550-554.	1.1	13
43	Impact of executive dysfunction on naming ability in multiple sclerosis. <i>Revue Neurologique</i> , 2019, 175, 552-559.	1.5	4
44	CLIPPERS and its mimics: evaluation of new criteria for the diagnosis of CLIPPERS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 1027-1038.	1.9	51
45	Immunoglobulin G4-related hypertrophic pachymeningitis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019, 6, e568.	6.0	41
46	Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. <i>Revue Neurologique</i> , 2019, 175, 341-357.	1.5	15
47	Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 31, 173-188.	2.0	44
48	Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731983666.	1.0	23
49	Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France. <i>Journal of Neurology</i> , 2019, 266, 888-901.	3.6	8
50	Multiple sclerosis with atypical MRI presentation: Results of a nationwide multicenter study in 57 consecutive cases. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 109-116.	2.0	9
51	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1809-1818.	3.0	55
52	De novo convulsive status epilepticus in patients with multiple sclerosis treated with dalfampridine. <i>Multiple Sclerosis Journal</i> , 2019, 25, 618-621.	3.0	4
53	Cerebrospinal fluid chitinase-3-like protein 1 level is not an independent predictive factor for the risk of clinical conversion in radiologically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2019, 25, 669-677.	3.0	28
54	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. <i>Multiple Sclerosis Journal</i> , 2019, 25, 591-600.	3.0	13

#	ARTICLE	IF	CITATIONS
55	Cervical spinal cord atrophy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e435.	6.0	57
56	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. <i>Neurology</i> , 2018, 90, e1858-e1869.	1.1	401
57	Anomalies Characteristic of Central Nervous System Demyelination. <i>Neurologic Clinics</i> , 2018, 36, 59-68.	1.8	15
58	Digestive side-effects with teriflunomide: Thoughts on lactose. <i>Revue Neurologique</i> , 2018, 174, 722-725.	1.5	3
59	Investigating the Effect of Teriflunomide on Diffuse Brain Tissue Damage in the Phase 3 TEMSO Study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 26, 258-259.	2.0	1
60	Gender Inequities in the Multiple Sclerosis Community: A Call for Action. <i>Annals of Neurology</i> , 2018, 84, 958-959.	5.3	10
61	Bevacizumab: Is the lower the better for glioblastoma patients in progression?. <i>Bulletin Du Cancer</i> , 2018, 105, 1135-1146.	1.6	3
62	MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study. <i>CNS Drugs</i> , 2018, 32, 661-672.	5.9	26
63	Should we treat patients with radiologically isolated syndrome (RIS)? Comments. <i>Revue Neurologique</i> , 2018, 174, 696-698.	1.5	2
64	Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients. <i>Journal of Neurology</i> , 2018, 265, 2251-2259.	3.6	29
65	Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs. <i>CNS Drugs</i> , 2018, 32, 939-949.	5.9	69
66	Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders. <i>Neurology and Therapy</i> , 2018, 7, 373-383.	3.2	31
67	Demyelinating diseases. <i>Revue Neurologique</i> , 2018, 174, 355.	1.5	0
68	Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies. <i>Neurology</i> , 2017, 88, 514-524.	1.1	49
69	Monitoring CD27 + memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study. <i>Journal of the Neurological Sciences</i> , 2017, 373, 335-338.	0.6	58
70	HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Disorders (HAND). <i>Heliyon</i> , 2017, 3, e00245.	3.2	17
71	Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. <i>Journal of Autoimmunity</i> , 2017, 79, 84-90.	6.5	67
72	Natalizumab-PML survivors with subsequent MS treatment. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e346.	6.0	12

#	ARTICLE	IF	CITATIONS
73	Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. <i>European Journal of Endocrinology</i> , 2017, 176, 769-777.	3.7	107
74	Multiple immune disorders after natalizumab discontinuation: After the CIRIS, the SIRIS?. <i>Revue Neurologique</i> , 2017, 173, 222-224.	1.5	7
75	Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one year. <i>Journal of the Neurological Sciences</i> , 2017, 382, 73-78.	0.6	4
76	Radiologically isolated syndrome in children. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e395.	6.0	41
77	A Case Report of Solitary Sclerosis: This is Really Multiple Sclerosis. <i>Neurology and Therapy</i> , 2017, 6, 259-263.	3.2	12
78	Treating asymptomatic bacteriuria before immunosuppressive therapy during multiple sclerosis: Should we do it?. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 161-163.	2.0	3
79	Radiologically isolated syndrome should be treated with disease-modifying therapy " Commentary. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1821-1823.	3.0	6
80	Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2017, 82, 186-195.	5.3	14
81	Multiple sclerosis treatments and the anti-JCV antibody index. <i>Revue Neurologique</i> , 2017, 173, e1.	1.5	0
82	New insights into the burden and costs of multiple sclerosis in Europe: Results for France. <i>Multiple Sclerosis Journal</i> , 2017, 23, 65-77.	3.0	23
83	Hypertension intracrânienne idiopathique dans le cadre d'une obésité ou d'un surpoids : Étude observationnelle. <i>Diabetes and Metabolism</i> , 2017, 43, A100.	2.9	0
84	A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication. <i>Journal of NeuroVirology</i> , 2017, 23, 216-225.	2.1	19
85	Signes et symptômes de la sclérose en plaques. , 2017, , 3-78.		0
86	Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. <i>PLoS ONE</i> , 2017, 12, e0168834.	2.5	25
87	Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study. <i>PLoS ONE</i> , 2017, 12, e0188120.	2.5	24
88	Diagnostic positif de la sclérose en plaques. , 2017, , 79-111.		0
89	False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1231-1234.	3.0	13
90	MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1719-1731.	3.0	249

#	ARTICLE	IF	CITATIONS
91	Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders. <i>Journal of the Neurological Sciences</i> , 2016, 368, 334-336.	0.6	17
92	Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis. <i>Journal of Neuroimmunology</i> , 2016, 298, 79-81.	2.3	42
93	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. <i>Neurology</i> , 2016, 87, 2491-2494.	1.1	18
94	Primary <sc>P</sc>rogressive <sc>M</sc>ultiple <sc>S</sc>clerosis <sc>E</sc>volving <sc>F</sc>rom <sc>R</sc>adiologically <sc>I</sc>solated <sc>S</sc>yndrome. <i>Annals of Neurology</i> , 2016, 79, 288-294.	5.3	130
95	Evaluation of quality of life and fatigue in radiologically isolated syndrome. <i>Revue Neurologique</i> , 2016, 172, 392-395.	1.5	20
96	Should a psychotic or manic episode be considered an early manifestation of Multiple Sclerosis? A multiple case study. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 6, 93-96.	2.0	10
97	Comparative efficacy of fingolimod vs natalizumab. <i>Neurology</i> , 2016, 86, 771-778.	1.1	71
98	Long-term safety and efficacy of teriflunomide. <i>Neurology</i> , 2016, 86, 920-930.	1.1	108
99	Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study. <i>Journal of the Neurological Sciences</i> , 2016, 363, 69-76.	0.6	42
100	Country break-out session highlights. <i>Neurodegenerative Disease Management</i> , 2015, 5, 31-37.	2.2	0
101	High doses of biotin in chronic progressive multiple sclerosis: A pilot study. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 159-169.	2.0	191
102	Adult-onset genetic leukoencephalopathies: A MRI pattern-based approach in a comprehensive study of 154 patients. <i>Brain</i> , 2015, 138, 284-292.	7.6	58
103	Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. <i>Journal of Neurology</i> , 2015, 262, 2329-2335.	3.6	86
104	Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. <i>Lancet</i> , 2015, 386, 974-981.	13.7	144
105	Tear analysis as a tool to detect oligoclonal bands in radiologically isolated syndrome. <i>Revue Neurologique</i> , 2015, 171, 390-393.	1.5	23
106	The radiologically isolated syndrome. <i>Revue Neurologique</i> , 2015, 171, 698-706.	1.5	21
107	Solitary sclerosis: Experience from three French tertiary care centres. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1216-1216.	3.0	11
108	Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. <i>PLoS ONE</i> , 2015, 10, e0132033.	2.5	48

#	ARTICLE	IF	CITATIONS
109	A Prospective Study of Patients with Brain MRI Showing Incidental T2 Hyperintensities Addressed as Multiple Sclerosis: a Lot of Work to do Before Treating. <i>Neurology and Therapy</i> , 2014, 3, 123-132.	3.2	22
110	The HV3 Score: A New Simple Tool to Suspect Cognitive Impairment in Multiple Sclerosis in Clinical Practice. <i>Neurology and Therapy</i> , 2014, 3, 113-122.	3.2	6
111	Switching From Natalizumab to Fingolimod in Multiple Sclerosis. <i>JAMA Neurology</i> , 2014, 71, 436.	9.0	133
112	Moving to Fingolimod From Natalizumab in Multiple Sclerosis—Reply. <i>JAMA Neurology</i> , 2014, 71, 925.	9.0	2
113	Risk for Nevus Transformation and Melanoma Proliferation and Invasion During Natalizumab Treatment. <i>JAMA Dermatology</i> , 2014, 150, 901.	4.1	13
114	Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1135-1139.	3.0	20
115	Demonstration of a lexical access deficit in relapsing-remitting and secondary progressive forms of multiple sclerosis. <i>Revue Neurologique</i> , 2014, 170, 527-530.	1.5	6
116	Uncommon foreign body reaction caused by derivation drain mimicking high grade CNS tumor. <i>Journal of the Neurological Sciences</i> , 2014, 340, 237-238.	0.6	0
117	Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event. <i>PLoS ONE</i> , 2014, 9, e90509.	2.5	254
118	Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?. <i>Aids</i> , 2014, 28, 493-501.	2.2	55
119	Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study. <i>Journal of NeuroVirology</i> , 2013, 19, 376-382.	2.1	29
120	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , 2013, 45, 1353-1360.	21.4	1,213
121	<scp>l</scp> -Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. <i>Neurology</i> , 2013, 81, 865-871.	1.1	140
122	Longitudinal follow-up of vision in a neuromyelitis optica cohort. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1320-1322.	3.0	24
123	Treat patients with radiologically isolated syndrome when the MRI brain scan shows dissemination in time: Yes. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1531-1532.	3.0	9
124	Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1297-1302.	3.0	53
125	Les traitements de premiÃ©re ligne dans la sclÃ©rose en plaques. <i>Pratique Neurologique - FMC</i> , 2012, 3, 73-89.	0.1	0
126	Increased risk of multiple sclerosis relapse after in vitro fertilisation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 796-802.	1.9	102

#	ARTICLE	IF	CITATIONS
127	Rituximab in refractory and non-refractory myasthenia: A retrospective multicenter study. <i>Muscle and Nerve</i> , 2012, 46, 687-691.	2.2	63
128	Endermology: A treatment for injection-induced lipoatrophy in multiple sclerosis patients treated with sub cutaneous glatiramer acetate. <i>Clinical Neurology and Neurosurgery</i> , 2011, 113, 721-724.	1.4	7
129	Carnitine serum levels and levocarnitine administration in multiple sclerosis patients treated with natalizumab. <i>European Journal of Neurology</i> , 2011, 18, e63-e64.	3.3	1
130	EGFR immunolabeling pattern may discriminate low-grade gliomas from gliosis. <i>Journal of Neuro-Oncology</i> , 2011, 102, 171-178.	2.9	21
131	Cancer and multiple sclerosis in the era of disease-modifying treatments. <i>Journal of Neurology</i> , 2011, 258, 1304-1311.	3.6	52
132	Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. <i>Brain</i> , 2011, 134, 693-703.	7.6	96
133	A Benign Form of Neuromyelitis Optica. <i>Archives of Neurology</i> , 2011, 68, 918.	4.5	54
134	Cutaneous Side-effects of Immunomodulators in MS. <i>International MS Journal</i> , 2011, 17, 88-94.	0.3	13
135	Evolution of Nevi During Treatment With Natalizumab. <i>Archives of Dermatology</i> , 2010, 147, 72.	1.4	21
136	Les syndromes radiologiquement isolés. <i>Neurologie Com</i> , 2010, 2, 139-141.	0.0	0
137	Cognitive function in radiologically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2010, 16, 919-925.	3.0	116
138	GIANT URTICARIA AND PERSISTENT NEUTRALIZING ANTIBODIES AFTER THE FIRST NATALIZUMAB INFUSION. <i>Neurology</i> , 2010, 74, 1394-1395.	1.1	9
139	Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. <i>Multiple Sclerosis Journal</i> , 2010, 16, 87-92.	3.0	43
140	Association Between Clinical Conversion to Multiple Sclerosis in Radiologically Isolated Syndrome and Magnetic Resonance Imaging, Cerebrospinal Fluid, and Visual Evoked Potential. <i>Archives of Neurology</i> , 2009, 66, 841.	4.5	191
141	RECURRENT PERICARDITIS DUE TO NATALIZUMAB TREATMENT. <i>Neurology</i> , 2009, 72, 1616-1617.	1.1	5
142	Successful treatment of refractory generalized myasthenia gravis with rituximab. <i>European Journal of Neurology</i> , 2009, 16, 246-250.	3.3	100
143	Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 399-405.	3.0	101
144	Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France. <i>Multiple Sclerosis Journal</i> , 2008, 14, 933-939.	3.0	5

#	ARTICLE	IF	CITATIONS
145	Unexpected multiple sclerosis: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 195-198.	1.9	112
146	Cognitive Functions in Neuromyelitis Optica. <i>Archives of Neurology</i> , 2008, 65, 84-8.	4.5	98
147	Association of cancer and stroke: A population-based study. <i>Journal of Clinical Oncology</i> , 2008, 26, 20672-20672.	1.6	0
148	Acute Fulminant Demyelinating Disease. <i>Archives of Neurology</i> , 2007, 64, 1426.	4.5	148
149	Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2007, 13, 256-259.	3.0	190
150	More severe disability of North Africans vs Europeans with multiple sclerosis in France. <i>Neurology</i> , 2007, 68, 29-32.	1.1	57
151	Natural History of Multiple Sclerosis with Childhood Onset. <i>New England Journal of Medicine</i> , 2007, 356, 2603-2613.	27.0	631
152	Turcot syndrome confirmed with molecular analysis. <i>European Journal of Neurology</i> , 2007, 14, 470-472.	3.3	17
153	Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. <i>European Journal of Neurology</i> , 2007, 14, 391-398.	3.3	58
154	A longitudinal observational study of a cohort of patients with relapsing/remitting multiple sclerosis treated with glatiramer acetate. <i>European Journal of Neurology</i> , 2007, 14, 1266-1274.	3.3	12
155	Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. <i>Multiple Sclerosis Journal</i> , 2006, 12, 321-324.	3.0	41
156	Idiopathic acute transverse myelitis: Application of the recent diagnostic criteria. <i>Neurology</i> , 2005, 65, 1950-1953.	1.1	149
157	First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas. <i>European Journal of Neurology</i> , 2005, 12, 685-690.	3.3	45
158	Acute aphasia in multiple sclerosis. <i>Neurology</i> , 2004, 62, 974-977.	1.1	61
159	Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. <i>Journal of the Neurological Sciences</i> , 2004, 218, 73-77.	0.6	63
160	Long-term outcome of oligodendrogliomas. <i>Neurology</i> , 2004, 62, 1783-1787.	1.1	80
161	Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003, 9, 521-525.	3.0	131
162	Interferon- β treatment in patients with childhood-onset multiple sclerosis. <i>Journal of Pediatrics</i> , 2001, 139, 443-446.	1.8	116

#	ARTICLE	IF	CITATIONS
163	Nitroso-ureaâ€“cisplatin-based chemotherapy associated with valproate: Increase of haematologic toxicity. <i>Annals of Oncology</i> , 2001, 12, 217-220.	1.2	100
164	Up-front chemotherapy with fotemustine (F)/cisplatin (CDDP)/etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas. <i>European Journal of Cancer</i> , 2000, 36, 1026-1031.	2.8	38
165	Leukoencephalopathy in multiple myeloma: Two case reports. <i>Annals of Oncology</i> , 1999, 10, 1515-1517.	1.2	11
166	Nonconvulsive status epilepticus of frontal origin. <i>Neurology</i> , 1999, 52, 1174-1174.	1.1	107
167	Solitary meningeal plasmacytomas. <i>Annals of Oncology</i> , 1997, 8, 791-795.	1.2	10
168	Recurrent bowel occlusion with oral ondansetron with no side effects of the intravenous route: A previously unknown adverse event. <i>Annals of Oncology</i> , 1997, 8, 919-920.	1.2	7
169	Progressive spastic paraparesis revealing primary hyperparathyroidism. <i>Neurology</i> , 1994, 44, 178-178.	1.1	13
170	Common Brain Volume Signatures Associated with Immunosuppression and Viral Load in Over 1000 Adults Living with HIV Across 5 Continents: Findings from the ENIGMA-HIV Working Group. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0